Apogee to Present 52-Week Phase 2 Atopic Dermatitis Data in March 23 Webcast
Apogee Therapeutics will report Part A 52-week efficacy and safety results from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis on March 23, 2026. Management will discuss these outcomes in a live webcast and call at 8:00 a.m. ET, followed by an archived replay.
1. Conference Call Logistics
Apogee will host a live webcast and conference call on Monday, March 23, 2026 at 8:00 a.m. ET to discuss Part A 52-week Phase 2 APEX data; the live webcast is accessible via the Investors section on Apogee’s website, with a replay available after the call.
2. Part A 52-Week Data Focus
The upcoming report will detail key efficacy measures such as EASI-75 response rates and long-term safety outcomes for zumilokibart in patients with moderate-to-severe atopic dermatitis enrolled in Part A of the APEX trial over a full 52 weeks.
3. Zumilokibart Clinical Program
Zumilokibart (APG777) is Apogee’s lead biologic candidate engineered to optimize half-life and dosing, initially targeting atopic dermatitis and planned expansions into asthma and eosinophilic esophagitis based on its mechanism-targeted design.